VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viking Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$25.05−0.12 (-0.48%)
Close on Oct 19, 2026
- Market cap
- $2.91B
- P/E (TTM)
- –
- Dividend yield
- –
Viking Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -47.3%
Financial strength
- Current ratio
- 4.72
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 114.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 7.13
- Dividend yield
- –